Format

Send to

Choose Destination
Vaccine. 2010 Mar 19;28(14):2624-35. doi: 10.1016/j.vaccine.2010.01.014. Epub 2010 Jan 26.

Is it cost-effective to introduce rotavirus vaccination in the Dutch national immunization program?

Author information

1
University Medical Center Utrecht, Julius Center for Health Sciences and Primary Care, 3508 GA Utrecht, The Netherlands. m.j.j.mangen@uncutrecht.nl

Abstract

This study assessed whether the inclusion of two rotavirus (RV) vaccines in the Dutch national immunization programme is cost-effective. Costs and outcomes in unvaccinated and vaccinated populations are compared for a time period of 20 years. In the baseline, assuming competitive market forces in relation to vaccine costs, Rotarix is more cost-effective than RotaTeq, resulting in a cost-utility ratio (CUR) of euro 53,000 per DALY (third payer perspective) and euro 49,000 per DALY (societal perspective), but both considered as being not cost-effective. Vaccine-related costs, annual epidemic-size, and indirect protection are the major factors that determine cost-effectiveness of RV vaccination.

PMID:
20109593
DOI:
10.1016/j.vaccine.2010.01.014
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center